Medication info
Rinatiegen Duo Tablets 2.5/500 mg

Rinatiegen Duo Tablets 2.5/500 mg

Prescription medicationTabletOral
Ingredient · strength
Linagliptin›2.5mg / 1 tabletMetformin Hydrochloride›500mg / 1 tablet
Manufacturer / importer
AlboGen Korea Co., Ltd.
Appearance
Bright yellow, bilaterally convex, oval film-coated tablets
Packaging
30 tablets/bottle, 60 tablets/bottle, 100 tablets/bottle, 200 tablets/bottle
Approval status
Active

MFDS item code 201902607 · Approved 2019.04.25 · Insurance code 652607271

Summary

Main use
Improvement of glycemic control in patients with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The dose of this medicine should be determined based on each patient’s current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of each component: linagliptin 2.5 mg and metformin 1000 mg twice daily. This medicine is administered twice daily with meals. To reduce gastrointestinal adverse reactions associated with metformin use, the dose should be increased gradually. 1. Patients not currently receiving metformin: For patients with no prior antidiabetic drug treatment whose blood glucose is not adequately controlled with monotherapy, the initial dose of this medicine is 1 tablet of 2.5/500 mg twice daily; the dose may be increased to 1 tablet of 2.5/1000 mg twice daily. 2. Switching from concomitant use of linagliptin and metformin: Patients switching from concomitant linagliptin and metformin therapy to this medicine should take the same doses of linagliptin and metformin they were previously taking as the initial dose. 3. Patients whose blood glucose is not adequately controlled with concomitant insulin and metformin therapy: The initial dose of this medicine should be considered as linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient’s existing metformin dose. When this medicine is administered with insulin, a reduction in the insulin dose may be necessary to reduce the risk of hypoglycemia (see section 3. Patients requiring caution when administering this medicine in the Precautions for Use). No studies have evaluated the safety and efficacy of switching to this medicine in patients previously treated with other oral antihyperglycemic agents. Any change in treatment for type 2 diabetes may cause changes in glycemic control; therefore, caution and appropriate monitoring are required. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] 45≤~<60 ml/min or estimated glomerular filtration rate (eGFR) 45≤~<60 mL/min/1.73 m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Because the starting dose of metformin is 500mg or 850mg once daily, treatment should not be initiated with this medicine. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function decreases to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment Because this medicine contains metformin, it should not be administered to patients with hepatic impairment (see section 2. Patients in whom this medicine is contraindicated in the Precautions for Use).

Ingredients

Manufacturer
AlboGen Korea Co., Ltd.

Efficacy & effects

Improvement of glycemic control in patients with type 2 diabetes mellitus

View approved original text

This medication assists in blood sugar control for patients with type 2 diabetes by combining Linagliptin and Metformin. When used alongside dietary and exercise regimens, it can help manage blood sugar levels more effectively. It is a drug that aids in improving your blood sugar control.

How to take

Adult dose

The dose of this medicine should be determined based on each patient’s current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of each component: linagliptin 2.5 mg and metformin 1000 mg twice daily. This medicine is administered twice daily with meals. To reduce gastrointestinal adverse reactions associated with metformin use, the dose should be increased gradually. 1. Patients not currently receiving metformin: For patients with no prior antidiabetic drug treatment whose blood glucose is not adequately controlled with monotherapy, the initial dose of this medicine is 1 tablet of 2.5/500 mg twice daily; the dose may be increased to 1 tablet of 2.5/1000 mg twice daily. 2. Switching from concomitant use of linagliptin and metformin: Patients switching from concomitant linagliptin and metformin therapy to this medicine should take the same doses of linagliptin and metformin they were previously taking as the initial dose. 3. Patients whose blood glucose is not adequately controlled with concomitant insulin and metformin therapy: The initial dose of this medicine should be considered as linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient’s existing metformin dose. When this medicine is administered with insulin, a reduction in the insulin dose may be necessary to reduce the risk of hypoglycemia (see section 3. Patients requiring caution when administering this medicine in the Precautions for Use). No studies have evaluated the safety and efficacy of switching to this medicine in patients previously treated with other oral antihyperglycemic agents. Any change in treatment for type 2 diabetes may cause changes in glycemic control; therefore, caution and appropriate monitoring are required. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] 45≤~<60 ml/min or estimated glomerular filtration rate (eGFR) 45≤~<60 mL/min/1.73 m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Because the starting dose of metformin is 500mg or 850mg once daily, treatment should not be initiated with this medicine. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function decreases to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment Because this medicine contains metformin, it should not be administered to patients with hepatic impairment (see section 2. Patients in whom this medicine is contraindicated in the Precautions for Use).

Precautions

This drug may cause a rare but life-threatening serious side effect known as lactic acidosis, so it should not be used by patients with poor kidney function or those with heart or liver diseases. Additionally, patients who are allergic to the active ingredients or components of this medication, those with type 1 diabetes, pregnant or breastfeeding women, or individuals with acute infections or severe trauma should not take this medication. This medication lowers blood sugar, which may increase the risk of hypoglycemia when used with other blood sugar-lowering agents; therefore, dosage adjustments should be made according to a doctor's instructions if used together. Elderly patients with reduced kidney function should have their kidney function regularly monitored, and if kidney function is severely impaired, this medication should not be used. Adverse reactions such as acute pancreatitis or blistering skin diseases may occur, so if there are persistent abdominal pains or blisters on the skin, inform medical personnel immediately. Vitamin B12 deficiency may occur, hence, if anemia or neurological symptoms arise, Vitamin B12 levels should be measured and supplementary treatment should be provided as needed. This medication may interact with certain drugs, so if you are taking other medications, you must inform your doctor or pharmacist, and especially before and after undergoing radiological examinations, it should be temporarily discontinued. Pregnant women or those planning to become pregnant should ideally avoid using this drug, and it should also be avoided during breastfeeding. It is not recommended for children under 10 years old, as safety and efficacy have not been established. The effects on driving or machinery operation are unknown, but caution is needed as symptoms like hypoglycemia may occur. In cases of overdose, gastrointestinal disturbances may appear, and lactic acidosis may occur; therefore, immediate medical treatment should be sought. This medication should be stored out of reach of children, in a cool, dry place, and in its original container.

Side effects

Lactic acidosis, nasopharyngitis, hypersensitivity, angioedema, urticaria, decreased and deficiency of vitamin B12, hypoglycemia, taste disorder, cough, decreased appetite, diarrhea, constipation, nausea, pancreatitis, vomiting, abdominal pain, oral ulcer formation, abnormal liver function tests, hepatitis, pruritus, erythema, rash, vesicular pemphigoid, severe and disabling arthralgia, rhabdomyolysis, increased lipase, increased amylase, constipation, epigastric pain, small and large bowel inflammation, intestinal obstruction, gastritis, herpes zoster, cystitis, acute pyelonephritis, bronchitis, vestibular neuronitis, sepsis, pneumonia, decreased appetite, dehydration, hyperglycemia, cerebral infarction, speech disorder, Alzheimer's disease, chest pain, fever, facial edema, fatigue, chronic obstructive pulmonary disease, asthma, diabetic foot, skin lesions, liver metastasis, acute leukemia, basal cell carcinoma, non-small cell lung cancer, malignant pericardial effusion, gastric cancer, rectal cancer, pancreatic cancer, meniscus injury, pneumoconiosis, congestive heart failure, angina, acute myocardial infarction, unstable angina, cardiac arrest, diabetic retinopathy, acute kidney injury, end-stage renal disease, acute cholangitis, acute cholecystitis, cholangitis, dizziness, kidney transplant failure, pruritus, insomnia, depression, hypertension, erectile dysfunction, goiter, anxiety, mood disorder, contusion, bone contusion, concussion, bone fracture, hand fracture, drowsiness, palpitations, dry eyes, cataracts, eye discomfort, allergic conjunctivitis, polyuria, hematuria, hypotension, flushing, hearing loss, benign prostatic hyperplasia, altered mental status, nocturia, dermatitis, osteoarthritis, limb pain, dizziness, sensory loss, pain, chest discomfort, asthenia, decreased hemoglobin, increased potassium in the blood, increased creatinine in the blood, increased creatine phosphokinase in the blood, increased ALT, increased AST, increased triglycerides in the blood, male pattern baldness, hyperhidrosis, hair loss, dermatitis, anxiety, insomnia, depression, hypertension, dizziness, benign prostatic hyperplasia, angina, acute myocardial infarction, unstable angina, diarrhea, stomatitis, mediastinitis, vitreous hemorrhage, fever, ligament sprain, flank pain, myelodysplastic syndrome, vocal cord polyp, stomatitis, dyspepsia, epigastric pain, rectal bleeding, cheilitis, dental caries, enteritis, gastritis, stomatitis, increased creatinine in the blood, facial edema, hyperthermia, back pain, rotator cuff syndrome, headache, subdural effusion, corneal abrasion, falls, ligament sprain, upper limb fracture, voice disorder, dyspnea, epistaxis

Not everyone experiences these, and they can vary from person to person.

Storage

This medication is sensitive to air and moisture, so it must be stored in a tightly sealed container. The appropriate storage temperature is between 1 to 30 degrees Celsius, and it is advisable to avoid excessively hot or humid places.

Appearance and packaging

Appearance

Bright yellow, bilaterally convex, oval film-coated tablets

Package unit

30 tablets/bottle, 60 tablets/bottle, 100 tablets/bottle, 200 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.